je.st
news
Tag: lung
Coalminers call for inquiry after return of black lung disease in Queensland
2015-12-24 01:44:00| Climate Ark Climate Change & Global Warming Newsfeed
AAP: The miners union is calling for a public inquiry into the re-emergence of black lung disease in Queensland. Nine people have either been diagnosed with the chronic respiratory condition or are showing symptoms, according to the Construction, Forestry, Mining and Energy Union (CFMEU). The union wants a public investigation into why the debilitating disease has returned three decades after it was thought to have been wiped out. Its appalling that companies and regulatory bodies have let health...
Mercks KEYTRUDA (pembrolizumab) Significantly Improves Survival Compared to Chemotherapy in Previously-Treated Patients with Non-Small Cell Lung Cancer Whose Tumors Express Any Level of PD-L1
2015-12-19 16:55:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KEYNOTE-010 Published in The Lancet and to be Presented at the European Society for Medical Oncology (ESMO) Asia 2015 Congress KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced results from the pivotal KEYNOTE-010 study, the first study of its kind to evaluate the potential of an immunotherapy compared to chemotherapy based on prospective measurement of PD-L1 expression in patients with advanced non-small cell lung cancer (NSCLC). Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orCourtney Ronaldo, 908-236-1108orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
FDA approves Genentech drug for advanced lung cancer
2015-12-11 23:03:49| Biotech - Topix.net
The Food and Drug Administration on Friday conditionally approved an experimental Genentech drug for patients with a certain type of lung cancer who have few other options. Alecensa won accelerated approval for patients with advanced non-small cell lung cancer with a mutation in a gene called ALK who have relapsed after treatment with Pfizer Inc.'s Xalkori or who could not tolerate that drug.
Tags: advanced
drug
cancer
lung
Lilly and Merck Expand Immuno-oncology Collaboration with Phase III Nonsquamous Non-Small Cell Lung Cancer Trial
2015-11-19 12:30:12| Merck.com - Research & Development News
Dateline City: INDIANAPOLIS and KENILWORTH, N.J. INDIANAPOLIS and KENILWORTH, N.J. Eli Lilly and Company (NYSE: LLY) and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the extension of an existing collaboration to evaluate the safety and efficacy of the combination of Lillys ALIMTA (pemetrexed for injection) and Mercks KEYTRUDA (pembrolizumab) in a pivotal Phase III study in first-line nonsquamous non-small cell lung cancer (NSCLC). The study will be sponsored by Merck and will be open to patients with NSCLC in the first-line setting, regardless of PD-L1 status. Language: English read more
EPA Plan aims to prevent lung cancer deaths due to radon.
2015-11-13 14:31:07| Industrial Newsroom - All News for Today
EPA, American Lung Association, and partners are announcing plan for preventing 3,200 lung cancer deaths annually by 2020 through radon exposure reduction strategies. National Radon Action Plan: A Strategy for Saving Lives sets out strategies to drive changes needed to reduce exposure to radon, including requiring radon testing and reduction systems as a standard practice in housing finance and insurance programs, and institutionalizing radon risk reduction through building code requirements.
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] next »